DB:1CG

Stock Analysis Report

Executive Summary

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases.

Snowflake

Fundamentals

Excellent balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has CRISPR Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

0%

1CG

-2.3%

DE Biotechs

0.03%

DE Market


1 Year Return

3.1%

1CG

-6.9%

DE Biotechs

9.9%

DE Market

Return vs Industry: 1CG exceeded the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: 1CG exceeded the German Market which returned 9.9% over the past year.


Shareholder returns

1CGIndustryMarket
7 Day0%-2.3%0.03%
30 Day0%-3.1%4.4%
90 Day1.0%-9.6%13.6%
1 Year3.1%3.1%-6.7%-6.9%13.4%9.9%
3 Yearn/a52.7%50.8%25.6%14.6%
5 Yearn/a5.0%2.7%36.9%18.2%

Price Volatility Vs. Market

How volatile is CRISPR Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?

6.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1CG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1CG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1CG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1CG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1CG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1CG is overvalued based on its PB Ratio (6.6x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

-6.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1CG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1CG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1CG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1CG's revenue (6.6% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 1CG's revenue (6.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1CG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CRISPR Therapeutics performed over the past 5 years?

-54.7%

Historical annual earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Earnings Trend: 1CG is unprofitable, and losses have increased over the past 5 years at a rate of -54.7% per year.

Accelerating Growth: Unable to compare 1CG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1CG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 1CG has a negative Return on Equity (-54.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is CRISPR Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1CG's short term assets ($438.5M) exceeds its short term liabilities ($31.4M)

Long Term Liabilities: 1CG's short term assets (438.5M) exceeds its long term liabilities (95.2M)


Debt to Equity History and Analysis

Debt Level: 1CG is debt free.

Reducing Debt: 1CG had no debt 5 years ago.


Balance Sheet

Inventory Level: 1CG has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1CG's debt is not covered by short term assets (assets are -6.1709588731626E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1CG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 1CG has sufficient cash runway for 1.522581 years if free cash flow continues to reduce at historical rates of -70.2% each year.


Next Steps

Dividend

What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1CG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1CG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1CG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1CG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1CG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of CRISPR Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Samarth Kulkarni (40yo)

0yrs

Tenure

US$9,727,531

Compensation

Dr. Samarth Kulkarni, Ph.D., has been the Chief Executive Officer of CRISPR Therapeutics AG since December 1, 2017 and served as its President since May 4, 2017 until December 1, 2017 and its Chief Busines ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Samarth's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.0yrs

Average Tenure

52yo

Average Age

Experienced Management: 1CG's management team is not considered experienced ( 2 years average tenure), which suggests a new team.


Board Age and Tenure

1.8yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 1CG's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,732,29618 Jan 19
Abingworth LLP
EntityCompany
Shares65,934
Max PriceUS$29.18
BuyUS$878,42328 Dec 18
Vertex Pharmaceuticals Incorporated
EntityCompany
Shares40,198
Max PriceUS$21.87
BuyUS$1,915,33626 Dec 18
Vertex Pharmaceuticals Incorporated
EntityCompany
Shares90,742
Max PriceUS$21.89

Ownership Breakdown

Information is not available.


Management Team

  • Craig Mello

    Scientific Founder & Advisory Board Member

    • Tenure: 0yrs
  • Rodger Novak (52yo)

    Founder

    • Tenure: 1.8yrs
    • Compensation: US$645.57k
  • Shaun Foy

    • Tenure: 0yrs
  • Chad Cowan

    Scientific Founder

    • Tenure: 0yrs
  • Mike Tomsicek (53yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
    • Compensation: US$2.25m
  • Emmanuelle Charpentier

    Co-Founder & Scientific Advisory Board Member

    • Tenure: 0yrs
  • Matthew Porteus

    Scientific Founder & Advisory Board Member

    • Tenure: 0yrs
  • Samarth Kulkarni (40yo)

    CEO & Director

    • Tenure: 0yrs
    • Compensation: US$9.73m
  • James Kasinger (47yo)

    General Counsel & Secretary

    • Tenure: 2.3yrs
    • Compensation: US$3.16m
  • Tony Ho (53yo)

    Executive Vice President of Research & Development

    • Tenure: 2.1yrs
    • Compensation: US$4.15m

Board Members

  • Pablo Cagnoni (56yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$648.79k
  • Craig Mello

    Scientific Founder & Advisory Board Member

    • Tenure: 0yrs
  • Rodger Novak (52yo)

    Founder

    • Tenure: 1.8yrs
    • Compensation: US$645.57k
  • Dan Anderson

    Scientific Founder & Advisory Board Member

    • Tenure: 0yrs
  • Simeon George (42yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$643.79k
  • Bill Lundberg (56yo)

    Head of Scientific Advisory Board

    • Tenure: 1.6yrs
    • Compensation: US$2.58m
  • John Greene (53yo)

    Director

    • Tenure: 0.3yrs
  • Emmanuelle Charpentier

    Co-Founder & Scientific Advisory Board Member

    • Tenure: 0yrs
  • Matthew Porteus

    Scientific Founder & Advisory Board Member

    • Tenure: 0yrs
  • Samarth Kulkarni (40yo)

    CEO & Director

    • Tenure: 0yrs
    • Compensation: US$9.73m

Company Information

CRISPR Therapeutics AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CRISPR Therapeutics AG
  • Ticker: 1CG
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.463b
  • Listing Market Cap: US$2.249b
  • Shares outstanding: 54.66m
  • Website: https://www.crisprtx.com

Number of Employees


Location

  • CRISPR Therapeutics AG
  • Baarerstrasse 14
  • Zug
  • Zug
  • 6300
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRSPNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDOct 2016
1CGDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2016
0VRQLSE (London Stock Exchange)YesCommon SharesGBUSDOct 2016

Biography

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/25 22:31
End of Day Share Price2019/06/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.